AXGN vs MDT
AXGN: Axogen is a medical technology company dedicated to advancing the field of peripheral nerve repair through its portfolio of nerve allografts, conduits, and wrap technologies. MDT: Medtronic is a global healthcare technology leader dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and digital solutions.
Side-by-side fundamentals
| Metric | AXGN | MDT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $36.18 | $87.75 | |
| Market cap | $1.9B | $112.2B | |
| P/E as of 2026-10-08 | n/a | 23.54 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | n/a | 2.41 | |
| Net margin | -7.0% | +13.2% | MDT higher |
| Gross margin FY2025, SEC XBRL | +74.3% | n/a | |
| Operating margin | -3.5% | +17.8% | MDT higher |
| ROE | -12.2% | +9.7% | MDT higher |
| ROA | -7.1% | +5.2% | MDT higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.57 | AXGN lower |
| Revenue growth (YoY) as of 2026-09-03 | +23.6% | +8.4% | AXGN higher |
| Revenue CAGR (3y) SEC XBRL | +17.6% | +5.2% | AXGN higher |
| Dividend yield as of 2026-09-03 | n/a | +3.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | MDT higher |
| Beta as of 2026-09-03 | 0.68 | 0.36 | |
| 1-year return as of 2026-10-08 close | +110.8% | -10.3% | AXGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.